secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078060
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma Q2 net loss narrows to $0.9M; cash drops to $13.1M; Phase 2 COVID study planned
--------------------------------------------------------------------------------

- Net loss of $0.9M ($0.11/share) vs. $123.1M loss in Q2 2024 which included $117.5M acquisition charge.
- Revenue $2.7M (vs. $57K) from deferred revenue on mutual termination of an oncology license.
- Cash, cash equivalents and investments $13.1M as of June 30, down from $21.3M at Dec 31, 2024.
- Phase 2 ratutrelvir (COVID) study submitted to HREC in Australia; results expected by year-end 2025.
- Bird flu Phase 2 study deferred; BARDA stockpile discussions continue; Charles Parker named Interim CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925078060/0001104659-25-078060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925078060/tm2523498d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer